Investment Team
|
Spencer joined Venrock in 2009 and is focused on cleantech and life science investing. Prior to his study at Stanford, Spencer spent over a decade performing and managing genetic research around the globe. In collaboration with Aventis CropScience (acquired by Bayer), Spencer investigated new genes connecting environmental signals to plant growth. As a Marie Curie Fellow, at the Institute of Biotechnology (University of Cambridge), he described new components of stem cell division. Spencer's research has received numerous awards including honors at the UK Houses of Parliament for work that has led to the identification of a new set of compounds for treatment of malaria.
|
|
||||||||||||
